What Blood Tests Should You Get in Your 30s, 40s, and 50s?

Most people only encounter blood testing reactively — when a symptom prompts a clinical visit, or when a physician orders a routine panel during an annual check-up. Yet the scientific case for proactive, decade-specific biomarker monitoring is increasingly compelling. Physiological trajectories that determine long-term health outcomes — insulin sensitivity, hormonal balance, micronutrient status, inflammatory tone — do not emerge suddenly. They shift gradually, often silently, across years or decades before clinical thresholds are crossed.

Understanding which biomarkers are most informative at different life stages is not simply a matter of testing more. It reflects how biological risk evolves with age: the metabolic vulnerabilities of the 30s differ meaningfully from the hormonal transitions of the 40s, which in turn differ from the cardiometabolic and cellular challenges that accumulate in the 50s. A thoughtful biomarker strategy aligns measurement with biology — tracking the signals most likely to shift, and most likely to matter, at each stage.

1. Why Age-Stage Biology Changes What You Should Measure

Standard clinical chemistry panels — full blood count, basic metabolic panel, TSH — were designed to detect overt disease rather than to characterise early biological drift. They are valuable but incomplete. Many of the most clinically meaningful changes occurring between the ages of 30 and 60 are measurable years before they produce diagnostic abnormalities.

Insulin resistance, for example, may begin developing 10–15 years before a formal type 2 diabetes diagnosis. Research tracking glycaemic trajectories in the Whitehall II cohort demonstrated that glucose metabolism and insulin secretion began diverging from their healthy baselines more than a decade before clinical diabetes onset. Fasting glucose alone would miss this window entirely. A precision biomarker approach expands the measurable picture to include fasting insulin and HbA1c — collectively characterising where an individual sits on that trajectory.

Hormonal decline is similarly gradual. Testosterone, DHEA-S, and estradiol all follow characteristic trajectories that begin shifting in the mid-30s and accelerate differently in men and women through the 40s and 50s. Tracking these shifts proactively — rather than waiting for symptoms — is the foundation of hormone-aware health optimisation. The same principle applies to cellular energy markers like NAD⁺, which declines measurably with age and is rarely included in routine clinical panels.

2. Your 30s: Building a Personal Biological Baseline

The primary value of biomarker testing in your 30s is baseline establishment. The body is generally resilient during this decade, but the biological patterns that will define health at 50 and 60 begin to solidify now. Metabolic habits, nutritional sufficiency, hormonal trajectories, and inflammatory tone are all measurable — and correctable — before dysfunction becomes clinically apparent.

This is the decade to ask not "is something wrong?" but "where am I, and where am I heading?"

Biomarkers of priority in your 30s:

• Fasting glucose and fasting insulin: Standard fasting glucose captures late-stage glycaemic disruption. Fasting insulin is more sensitive for early insulin resistance, which may begin accumulating in the 30s in individuals with sedentary patterns, high-caloric diets, or significant chronic stress load. The HOMA-IR calculation — derived from fasting glucose and insulin together — provides a clinically interpretable estimate of insulin sensitivity without an oral glucose tolerance test.
• Vitamin D (25-OH): Vitamin D insufficiency is highly prevalent globally and is associated with immune dysregulation, impaired calcium homeostasis, and emerging evidence of its role in hormonal and metabolic pathways. Establishing Vitamin D status early allows targeted correction with a long intervention runway ahead.
• Active B12 (holotranscobalamin): Unlike total B12 — which includes biologically inactive bound fractions — holotranscobalamin (holoTC) represents the fraction of vitamin B12 actually available for cellular uptake. Functional B12 insufficiency may affect DNA methylation, homocysteine metabolism, and neurological function. This is particularly relevant for individuals on plant-based or reduced-animal-protein diets, a demographic increasingly common in the 30–40 age group.
• Ferritin: Iron storage status is one of the most actionable and frequently abnormal biomarkers in adults under 40, particularly in menstruating women and endurance athletes. Low ferritin can manifest as fatigue, reduced exercise tolerance, hair shedding, and impaired cognitive performance — all well before anaemia develops. It is also a biomarker that must be interpreted in context, as ferritin rises with inflammation even when iron stores are depleted. See our full deep-dive on Ferritin for interpretation guidance and clinical decision thresholds.
• Magnesium: Approximately 31% of the global population has inadequate magnesium intake. Magnesium is a cofactor in over 300 enzymatic reactions, including those governing energy metabolism, neuromuscular function, insulin signalling, and cortisol regulation. Serum magnesium is a blunt instrument — it remains within the reference range even as intracellular stores deplete — which makes clinical context critical for interpretation.
• Homocysteine: A functional biomarker at the intersection of methylation biology, folate-B12-B6 metabolism, and cardiovascular risk. Elevated homocysteine in your 30s may reflect methylation-pathway strain or micronutrient insufficiency that is highly correctable at this stage. For full interpretation guidance, including the surrounding biomarker cluster that makes homocysteine most clinically meaningful, see our Homocysteine deep-dive.
• DHEA-S: DHEA-S peaks in early adulthood and begins a gradual decline from the late 20s onward. Establishing a baseline value in the 30s provides crucial longitudinal reference for interpreting results in later decades, when the decline becomes more clinically significant. There is no meaningful value in a single mid-40s DHEA-S reading without a personal baseline to compare against.
• Testosterone (total and free): Establishing a hormonal baseline in the 30s — for both men and women — creates the reference point from which future change is most interpretable. Testosterone production declines by approximately 1–2% per year in men after age 30. A reading of 500 ng/dL at 48 means something very different if you were at 700 ng/dL at 34 versus 510 ng/dL at 34.
• Omega-3 Index (EPA + DHA): The Omega-3 Index reflects the proportion of EPA and DHA in red blood cell membranes — one of the most reliable assessments of long-term omega-3 status. Large-scale epidemiological data consistently links a low Omega-3 Index with elevated cardiovascular risk. Establishing a value in the 30s provides a modifiable, trackable baseline with the longest possible intervention window.

3. Your 40s: Metabolic Drift, Hormonal Shifts, and Silent Risk

The 40s are a critical decade for preventive biology. Several major physiological transitions accelerate during this period: insulin sensitivity typically declines, sex hormone levels shift meaningfully in both men and women, low-grade inflammation becomes more prevalent, and early cardiometabolic risk factors — lipid dysregulation, central adiposity — begin to consolidate. The challenge is that many of these changes produce few obvious symptoms until they have reached a stage that is harder to reverse.

This is the decade to shift from baseline-building to active longitudinal tracking — and to extend the panel to include cardiometabolic and cellular markers not yet a priority in the 30s.

Biomarkers of priority in your 40s:

• HbA1c: A three-month integrated measure of average blood glucose, HbA1c begins to be genuinely informative in the 40s as pre-diabetic trajectories become more prevalent. Research estimates that over 96 million U.S. adults have prediabetes, with approximately 80% unaware of it. Tracking HbA1c longitudinally — not simply checking it once — provides the clearest signal about glycaemic trajectory and the window for early intervention.
• Lipid panel (total cholesterol, HDL, LDL, triglycerides): Cardiovascular risk begins accumulating meaningfully in the 40s, particularly as hormonal shifts — falling oestrogen in women, declining testosterone in men — alter lipid metabolism. LDL and triglycerides tend to rise while HDL may fall. For individuals with family history or multiple risk factors, ApoB provides a more accurate assessment of atherogenic particle burden than LDL concentration alone.
• Testosterone (total and free) with SHBG: Total testosterone alone is often insufficient for interpretation. Sex hormone-binding globulin (SHBG) binds testosterone and regulates its bioavailability; SHBG tends to rise with age, reducing free testosterone even when total testosterone appears adequate. Measuring free or calculated free testosterone alongside SHBG and total testosterone provides a far more clinically meaningful picture. In women, testosterone levels also decline during the perimenopause transition, influencing libido, body composition, and energy regulation.
• DHEA-S: The decline of DHEA-S accelerates during the 40s, with values often falling to roughly half of the youthful peak by this stage. The cortisol/DHEA-S ratio — reflecting the balance between catabolic stress physiology and anabolic-resilience signalling — often shifts unfavourably with chronic stress load, disrupted sleep, and the lifestyle pressures that accumulate in this decade.
• Cortisol: While a single morning cortisol value has interpretive limitations, tracking cortisol trends over time — particularly in relation to DHEA-S — can provide meaningful insight into HPA axis loading. Chronically elevated or dysregulated cortisol has downstream consequences for immune function, body composition, sleep architecture, and metabolic health, all of which intersect with the physiological transitions of the 40s.
• NAD⁺: NAD⁺ levels decline measurably with age, with research suggesting a meaningful reduction beginning in the 40s. NAD⁺ is central to mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. Declining NAD⁺ has been associated with diminished cellular resilience and accelerated aging biology. For a full mechanistic overview, see our article on NAD⁺ levels and longevity.
• hs-CRP: High-sensitivity C-reactive protein is a sensitive but non-specific marker of systemic low-grade inflammation. Chronic low-level inflammation in the 40s has been associated with elevated cardiovascular risk, insulin resistance, and accelerated tissue aging. Interpreting hs-CRP alongside metabolic and hormonal markers helps contextualise the inflammatory substrate underlying these changes.
• Thyroid function (TSH, fT3, fT4): Thyroid dysfunction — particularly subclinical hypothyroidism — becomes more prevalent in the 40s and can present non-specifically as fatigue, weight gain, hair changes, or cognitive fog. Autoimmune thyroid conditions, notably Hashimoto's thyroiditis, have a peak onset window during this decade, particularly in women.

4. Your 50s: Cardiometabolic Risk, Cellular Aging, and Hormonal Transition

The 50s bring a convergence of biological challenges. In women, menopause produces a rapid and profound hormonal transition — with downstream effects on lipid metabolism, bone density, and cardiovascular risk — that typically unfolds between ages 45 and 55. In men, testosterone decline may accelerate, and the metabolic consequences of years of suboptimal function begin to compound. Cellular aging biology — NAD⁺ depletion, mitochondrial inefficiency, rising oxidative stress — also becomes clinically relevant in this decade in ways that are now measurable rather than theoretical.

The biomarker strategy in the 50s shifts again: this is the decade for comprehensive risk mapping and cellular health monitoring, with the personal baselines established in the 30s and 40s now serving as the interpretive scaffolding.

Biomarkers of priority in your 50s:

• HbA1c and fasting glucose (repeated, more frequently): Diabetes risk increases substantially after age 50. Semi-annual HbA1c tracking is strongly indicated, particularly in individuals who showed borderline or trending values in their 40s. The value here is not a single snapshot but a confirmed trajectory.
• Full lipid panel with cardiometabolic context: Post-menopausal women experience an accelerated deterioration in lipid profiles due to oestrogen withdrawal. Men with longstanding suboptimal metabolic function may show compounding lipid risk. Total cholesterol, LDL, HDL, triglycerides, and non-HDL cholesterol — or ideally ApoB — provide the most complete cardiometabolic risk picture at this stage.
• Testosterone (total and free) with SHBG: Clinically low testosterone becomes increasingly prevalent in men in their 50s, with estimates suggesting 6–12% of men in their 40s and a higher proportion in their 50s have total testosterone below 300 ng/dL. For women, monitoring testosterone alongside estradiol during and after menopause provides a broader picture of the hormonal environment influencing body composition, bone density, and cognitive function.
• Estradiol and FSH (women): Estradiol falls sharply during menopause, and follicle-stimulating hormone (FSH) rises as the ovaries become less responsive to gonadotropin signalling. Tracking this transition provides data that can inform decisions about lifestyle interventions, hormone therapy considerations, and bone health management.
• DHEA-S and the cortisol/DHEA-S ratio: By the 50s, DHEA-S has typically declined to roughly 25–30% of its youthful peak. The DHEA-S/cortisol ratio — sometimes described as a marker of allostatic load — often shows its most unfavourable shift in this decade, particularly in individuals with chronic stress exposure or disrupted sleep patterns.
• NAD⁺: The case for tracking NAD⁺ is arguably strongest in the 50s. By this decade, the gap between current NAD⁺ levels and those associated with optimal cellular function is at its most pronounced. Measuring NAD⁺ provides an objective baseline from which to assess the impact of NAD⁺ precursor interventions (NMN, NR) and lifestyle strategies. For a full scientific overview, see our NAD⁺ deep-dive.
• Vitamin D: Vitamin D insufficiency becomes especially consequential in the 50s, given its role in bone mineral metabolism, immune regulation, and its emerging associations with cardiometabolic health. Post-menopausal women face accelerated bone density loss, making Vitamin D status highly actionable in this decade.
• Active B12 and homocysteine: Cognitive aging risk rises with age. Elevated homocysteine has been consistently associated with increased risk of cognitive decline and dementia in longitudinal studies. Ensuring adequate Active B12 — interpreted alongside homocysteine and methylmalonic acid (MMA) — provides one of the most modifiable intervention points in cognitive aging prevention.
• Creatinine and kidney function (eGFR): Age-related decline in glomerular filtration rate becomes measurable in the 50s. Creatinine and eGFR are important both for clinical risk context and for interpreting other biomarkers that are affected by renal clearance — including homocysteine, which rises with impaired kidney function independently of B-vitamin status.
• hs-CRP (continued tracking): Chronic low-grade inflammation is recognised as a central driver of age-related disease — from cardiovascular events to sarcopenia to cognitive decline. Regular hs-CRP tracking in the 50s, interpreted alongside lipid, metabolic, and hormonal context, reveals whether inflammatory burden is stable, worsening, or responding to intervention.

5. Biomarker Mapping: Decade-by-Decade Reference

The following maps biomarkers across biological systems and decades of priority, with their measurement methods noted for analytical reference.

Metabolic and Glycaemic Axis

• Fasting insulin + HOMA-IR: Primary in 30s; important metabolic tracker across all decades — method: enzymatic immunoassay
• Fasting glucose: Universal; more sensitive when paired with insulin for early insulin resistance — method: enzymatic clinical chemistry
• HbA1c: Priority from 40s onward; critical as pre-diabetic window opens — method: HPLC or immunoturbidimetric assay

Lipid and Cardiovascular Axis

• Total cholesterol, HDL, LDL, triglycerides: Active monitoring from 40s; critical in 50s especially in post-menopausal women — method: enzymatic clinical chemistry
• ApoB (extended marker): Captures atherogenic particle burden more precisely than LDL alone — method: immunoturbidimetry
• hs-CRP: Meaningful from 40s; critical inflammatory risk assessment in 50s — method: high-sensitivity immunoturbidimetry

Hormonal Axis

• Testosterone (total + free) + SHBG: Baseline in 30s; active monitoring in 40s and 50s — method: LC-MS/MS or immunoassay
• DHEA-S: Baseline in 30s; longitudinal tracking essential in 40s and 50s — method: immunoassay or LC-MS/MS
• Cortisol: Context biomarker; most informative alongside DHEA-S — method: immunoassay
• Estradiol + FSH (women): Increasingly relevant from perimenopause through 50s — method: immunoassay or LC-MS/MS

Nutritional and Micronutrient Axis

• Active B12 (holoTC): Priority from 30s; increasingly critical in 50s for cognitive aging context — method: immunoassay
• Vitamin D (25-OH): Universal across all decades; especially critical in 50s — method: LC-MS/MS or immunoassay
• Magnesium: Universal; interpret with clinical context given limitations of serum measurement — method: colorimetric clinical chemistry
• Ferritin: Priority in 30s and 40s; interpret alongside CRP to rule out inflammation-driven elevation — method: immunoassay
• Omega-3 Index (EPA + DHA): Baseline in 30s; key cardiovascular and neurological longevity marker — method: fatty acid profiling via GC or LC-MS/MS
• Homocysteine: Relevant across all decades as methylation and cognitive risk marker — method: LC-MS/MS or immunoenzymatic assay → deep-dive

Cellular Energy and Aging Axis

• NAD⁺: Most clinically relevant from 40s onward; central to mitochondrial function and DNA repair — method: HPLC or LC-MS/MS (intracellular quantification) → deep-dive

6. The Principle of Personal Reference Points

One principle cuts across every decade and every biomarker: the interpretive value of a personal baseline. A single biomarker result, taken without context, is informative but limited. Its full analytical value emerges when compared against your own biology from years earlier.

This is why beginning structured biomarker tracking in the 30s is not premature — it builds the longitudinal substrate against which every future result becomes more interpretable. A testosterone reading of 420 ng/dL at age 48 carries different clinical meaning if your value at age 34 was 680 ng/dL compared to 430 ng/dL. The trajectory is the signal. This is equally true for NAD⁺, DHEA-S, HbA1c, and ferritin — all biomarkers where direction of change over time is often more meaningful than any single cross-sectional value.

For a broader overview of the biomarkers most closely associated with healthy aging outcomes, see our article on Top Biomarkers for Longevity.

7. How Biostarks Can Help

Biostarks panels are designed around the kind of comprehensive, analytically rigorous biomarker coverage that decade-specific health optimisation requires. Rather than a single-dimension clinical chemistry screen, each panel is structured around biomarker clusters that reflect real physiological systems — and that evolve with your biological needs.

The Nutrition Panel covers 30 essential biomarkers including Active B12, Vitamin D, Magnesium, Ferritin, the Omega-3 Index, Cortisol, and Total Testosterone — making it a strong foundation test for the 30s and an ongoing baseline for nutritional and hormonal tracking. For those in their 40s and 50s where cardiometabolic and metabolic risk becomes more pressing, the Metabolic Health Panel extends the picture to include HbA1c, fasting glucose, a full lipid panel (LDL, HDL, triglycerides, total cholesterol), creatinine, cortisol, and testosterone — a 39-biomarker comprehensive assessment mapped directly to the priorities of this life stage. For individuals specifically focused on cellular energy and NAD⁺ decline, the Longevity NAD⁺ Panel measures intracellular NAD⁺ using high-resolution mass spectrometry, alongside essential minerals that contextualise mitochondrial function.

All analyses are processed in Switzerland using high-resolution mass spectrometry, with results delivered on a secure digital platform with clear, biomarker-by-biomarker interpretation tailored to your profile and goals.

8. References

• Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study — The Lancet — Tabák AG et al. — (2009) — Source
• Vitamin D deficiency — New England Journal of Medicine — Holick MF — (2007) — Source
• The interplay between magnesium and testosterone in modulating physical function in men — International Journal of Endocrinology — Maggio M et al. — (2014) — Source
• Longitudinal effects of aging on serum total and free testosterone levels in healthy men — Journal of Clinical Endocrinology & Metabolism — Harman SM et al. — (2001) — Source
• NAD+ intermediates: the biology and therapeutic potential of NMN and NR — Cell Metabolism — Yoshino J et al. — (2018) — Source
• Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults — American Journal of Medicine — Kado DM et al. — (2005) — Source
• Sex and gender differences in cardiovascular disease prevention: what a difference a decade makes — Circulation — Mosca L et al. — (2011) — Source
• Iron deficiency — Blood — Camaschella C — (2019) — Source
• DHEA and aging: interactions, effects, and clinical significance — Hormones (Athens) — Genazzani AD et al. — (2020) — Source
• C-reactive protein: a simple test to predict risk of heart attack and stroke — Circulation — Ridker PM — (2003) — Source
• The omega-3 index as a risk factor for cardiovascular disease — Prostaglandins, Leukotrienes and Essential Fatty Acids — Harris WS — (2007) — Source
• International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes — Diabetes Care — International Expert Committee — (2009) — Source